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In Brief
FGF15 is synthesized in the intestine and
represses liver bile acid metabolism.
Detection of circulating FGF15 has
however been difficult. Katafuchi et al.
describe a sensitive mass spectrometry
technique to measure FGF15
concentrations in plasma, supporting its
identity as a hormone.
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Fibroblast growth factor 15 (FGF15) has been pro-
posed as a postprandial hormone that signals from
intestine to liver to regulate bile acid and carbohy-
drate homeostasis. However, detecting FGF15 in
blood using conventional techniques has proven
difficult. Here, we describe a stable isotope stan-
dards and capture by anti-peptide antibodies
(SISCAPA) assay that combines immuno-enrichment
with selected reaction monitoring (SRM) mass spec-
trometry to overcome this issue. Using this assay, we
show that FGF15 circulates in plasma in an FXR and
circadian rhythm-dependent manner at concentra-
tions that activate its receptor. Consistent with the
proposed endocrine role for FGF15 in liver, mice
lacking hepatocyte expression of the obligate
FGF15 co-receptor, b-Klotho, have increased bile
acid synthesis and reduced glycogen storage
despite having supraphysiological plasma FGF15
concentrations. Collectively, these data demonstrate
that FGF15 functions as a hormone and highlight the
utility of SISCAPA-SRM as a sensitive assay for de-
tecting low-abundance proteins in plasma.
INTRODUCTION
FGF15 is a member of a subfamily of FGFs, including FGF19,
FGF21, and FGF23, which function as hormones (Beenken and
Mohammadi, 2009). FGF15 is the mouse ortholog of human
FGF19, although they share only 50% amino acid identity (Katoh
and Katoh, 2003). Expression of both Fgf15 and FGF19 is stim-
ulated in the ileum by the bile acid receptor, FXR, during the
postprandial reuptake of bile acids (Inagaki et al., 2005; Lunda˚-
sen et al., 2006). Current evidence suggests that both FGF15
and FGF19 are secreted from enterocytes and transported to898 Cell Metabolism 21, 898–904, June 2, 2015 ª2015 Elsevier Inc.liver, where they bind and activate a heteromeric receptor com-
plex composed of fibroblast growth factor receptor 4 (FGFR4)
and b-Klotho in hepatocytes. This results in transcriptional
repression of CYP7A1, which encodes the rate-limiting enzyme
in bile acid synthesis (reviewed in de Aguiar Vallim et al., 2013;
Potthoff et al., 2012). Genetic loss and gain-of-function studies
of various components in this signaling pathway, including
FXR, FGF15, and FGFR4, have demonstrated the pathway’s
physiologic significance in bile acid homeostasis in mouse (Ina-
gaki et al., 2005; Yu et al., 2000). FGF19 is readily detectable in
human serum by standard ELISA, and its circulating levels are
inversely correlated with bile acid synthesis (Lunda˚sen et al.,
2006; Walters et al., 2009). However, for unknown reasons,
FGF15 is a weak antigen, and ELISAs to detect FGF15 in the
blood have not been available, leading to questions about
whether it is a true hormone (Angelin et al., 2012).
Here we describe the application of a technique called stable
isotope standards and capture by anti-peptide antibodies
(SISCAPA) (Anderson et al., 2004) that combines the power of
targeted mass spectrometry (Mirzaei et al., 2013) and immuno-
purification to definitively measure FGF15 concentrations in
plasma. By employing SISCAPA together with the hepatocyte-
specific knockout of b-Klotho, we provide unequivocal evidence
for the role of intestine-derived FGF15 in the gut-liver endocrine
axis that governs bile acid synthesis. Further, this work highlights
the potential of SISCAPA for studying low-abundance endocrine
factors that are otherwise refractory to detection.
RESULTS AND DISCUSSION
The SISCAPA-SRM Assay
Plasma has one of the most complex proteomes in terms of both
the number of proteins and their range of concentrations.
Because the dynamic range of protein concentrations in plasma
can range over 10 orders of magnitude (Hortin and Sviridov,
2010), achieving deep coverage of the plasma proteome has
been difficult. Selected reaction monitoring (SRM) is currently
the most sensitive mass spectrometry technique for the detec-
tion of peptides in complex mixtures (Picotti et al., 2013). This
AB
Figure 1. The SISCAPA-SRM Assay
(A) Workflow used for the development of the
FGF15 SISCAPA-SRM assay. His-tagged FGF15
was purified from the lysate of HEK293 cells
overexpressing the target. The affinity-purified
sample was then digested and analyzed by
shotgun MS for identification of peptides gener-
ated from FGF15. The three peptides (all proteo-
typic) with highest ion intensity and best chro-
matographic behavior were then selected and
chemically synthesized. SRM alone was per-
formed for plasma spiked with heavy labeled ver-
sions of the tryptic peptide. Rabbit antibodies were
raised against the selected peptides and used for
peptide enrichment from plasma digests. Only one
of the target peptides was chosen for SRM after
the affinity enrichment due to differences in anti-
body affinities and peptide ionization efficiencies.
A heavy-isotope coded version of the detected
peptide was added to the plasma digest prior to
enrichment as an internal standard (IS) for absolute
quantification.
(B) SRM traces are shown for both the light (red)
and heavy (blue) y ions of FGF15-176 peptide
(SFFETGDQLR) antibody-enriched from the digest
of the plasma collected from wild-type (WT) and
Fgf15-KO mice. Heavy (H) and light (L) ions are
labeled y5, y6, and y8.technique, which relies on quadrupole mass analyzers, achieves
superior sensitivity by sequential ion and fragment ion filtering
instead of trapping. However, even SRM is limited by the ioniza-
tion efficiency of peptides in complex mixtures. For this reason,
SISCAPA technology was developed to achieve even greater
sensitivity by combining the power of immunopurification of pep-
tide surrogates of target proteins and SRM (Anderson et al.,
2004).
Western blot assays and ELISAs commonly used for protein
detection and quantification rely on antibodies. In cases where
high-affinity antibodies cannot be raised and where SRM is not
adequately sensitive, SISCAPA is a remaining option. SISCAPA
uses peptide-specific antibodies to enrich peptides from pro-
teins of interest for SRM analysis (Figure 1A). Antibodies are
developed against those peptides unique to the target protein
(proteotypic peptides) and with the best ionization efficiency
and chromatographic behavior. These antibodies are then
used to enrich the target peptides from a complex protein digest.
Stable heavy isotope-labeled peptide(s) are added to theCell Metabolism 21, 898–protein digest prior to peptide immuno-
purification as internal standards for
SRM quantification.
Detection of FGF15 in Plasma by
SISCAPA-SRM
As a first step toward developing a
SISCAPA-SRM assay for FGF15, we
determined which FGF15 peptides to
monitor by SRM. FGF15 was expressed
in HEK293 cells and enriched by nickel-
affinity chromatography (Inagaki et al.,2005). The eluate was then digested with trypsin and analyzed
by shotgun mass spectrometry. Over 700 proteins were de-
tected in this purified sample based on a search of the data
with CPFP version 2.0.3. (Trudgian and Mirzaei, 2012; Trudgian
et al., 2010) and are listed in Table S1. Three proteotypic
FGF15 peptides, FGF15-52 (LQYLYSAGPYVSNCFLR), FGF15-
176 (SFFETGDQLR), and FGF15-188 (MFSLPLESDSMDPFR),
were detected (19.3% sequence coverage).
The SRM method was developed by determining the top
seven transitions for heavy-labeled FGF15-52, FGF15-176, and
FGF15-188 peptides based on injection of a mixture containing
50 fmol of each peptide. Once selected, the corresponding
‘‘light’’ endogenous FGF15 peptide transitions were generated
by making the necessary m/z adjustments to the transitions.
The liquid chromatography (LC)methodwas optimized by inject-
ing spiked plasma samples and using 15, 30, and 45 min gradi-
ents for separation to determine what gradient length provided
the optimal combination of chromatographic separation and
sensitivity. A 45 min gradient resulted in minimal peak904, June 2, 2015 ª2015 Elsevier Inc. 899
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Figure 2. Quantification of Plasma FGF15
upon FXR Activation
(A–C) WT and Fgf15-KO mice were treated with
vehicle (open bars) or 100 mg/kg GW4064 (filled
bars) for 5 hr after a 5 hr fast. (A) Ileal Fgf15mRNA
expression. (B) Plasma FGF15 levels quantified by
SISCAPA. (C) Hepatic Cyp7a1 mRNA expression.
(D) ERK2 phosphorylation upon stimulation with
recombinant FGF15. Serum-starved H4IIE rat
hepatoma cells were stimulated for 10min with the
indicated concentration of recombinant mouse
FGF15. The phosphorylated and total ERK2
(P-ERK2 and T-ERK2, respectively) levels were
analyzed from immunoblots (shown in the insets)
of identical aliquots of the same samples run on
concurrent gels. Images were quantified using
ImageQuant LAS4000 software.
Data are shown as the mean ± SEM, n = 5–6/
group. *p < 0.05, **p < 0.01, ***p < 0.001 compared
to vehicle. n.d., not detected.broadening relative to the shorter gradients and provided better
contaminant separation and was therefore used for the subse-
quent SRM analyses. The limit of detection (LOD) for FGF15 in
plasma based on this SRM analysis, assuming complete tryptic
digestion of FGF15, was determined to be 42.3 ng/ml. Addition-
ally, the LOD for the FGF15-176 peptide by SRM was 5 times
lower than that for the FGF15-188 peptide and 36 times lower
than that for the FGF15-52 peptide. However, we were unable
to directly detect the three FGF15 peptides by SRM in plasma
frommice, even after treatment for 6 hr with the potent, selective
FXR agonist, GW4064 (Goodwin et al., 2000). Thus, based on the
LOD of SRM, the level of FGF15 in plasma was predicted to be
below 42.3 ng/ml.
To overcome this limitation, we generated rabbit polyclonal
antisera against each of the three FGF15 peptides for the pur-
poses of enrichment. Antibodies against each peptide were pu-
rified by peptide affinity chromatography and evaluated by
ELISA. Antibodies against FGF15-176 had the highest affinity
for their cognate peptide (Figure S1), coinciding with the lowest
LOD of this antigen. The FGF15-176 peptide was also the best-
performing peptide based on ionization efficiency and detect-
ability by SRM alone. Thus, the FGF15-176 antiserum was
used to develop the SISCAPA-SRM assay (Figure 1A).
For detection of FGF15 in plasma, 30 ml of plasma were di-
gested overnight with trypsin. Twenty femtomoles of labeled
peptide were added for quantification, and tryptic peptides
were purified using reversed-phase sorbent cartridges. For anti-
body immobilization, FGF15 antiserum was mixed with 10 ml of
protein G agarose beads (approximately 50% slurry) and 25 ml
of PBS and incubated for 45min at room temperature with gentle
shaking. Affinity-purified FGF15-176 antibodies were not used
because the preparations contained detectable levels of co-900 Cell Metabolism 21, 898–904, June 2, 2015 ª2015 Elsevier Inc.eluted peptide from the affinity matrix,
which would have contributed back-
ground to the SISCAPA-SRM assay.
Moreover, as demonstrated below, the
unpurified antiserum provided adequate
sensitivity. The antibody-protein G beadswere washed twice with 0.2 M triethanolamine/PBS (pH 8.5) and
the antibodies cross-linked to the beads with dimethyl pimelimi-
date (DMP). The conjugated beads were mixed with the sample
in PBS containing 0.04% RapiGest (Waters) and incubated at
4C with gentle shaking overnight. The peptides were eluted
the following day using 5%acetic acid. The eluatewas subjected
to solid-phase extraction on an Oasis HLB plate and eluted with
40% ACN, 0.1% TFA in order to extract the FGF15-176 peptide
without elution of more hydrophobic species that contaminate
the LC/MS system. The eluate was dried and reconstituted for
SRM analysis. Although SISCAPA enriches FGF15 for LC/MS
analysis, a 45 min HPLC gradient was used to distinguish the
FGF15-176 peptide from non-specifically bound peptides with
similar retention times.
We first tested the FGF15 SISCAPA-SRM assay using left ven-
tricular plasma from fedwild-type and Fgf15-knockout (KO)mice
(Wright et al., 2004). Quantification by SISCAPA-SRM revealed
the presence of FGF15 in plasma from WT mice, but not
Fgf15-KO mice (Figure 1B). The LOD for FGF15 using the
SISCAPA-SRM assay was 0.1 ng/ml (S/N = 3). We then evalu-
ated FGF15 mRNA and plasma protein levels in fasted wild-
type and Fgf15-KO mice treated with either vehicle or the FXR
agonist, GW4064, for 6 hr. As expected, GW4064 treatment
increased Fgf15 mRNA in ileum of wild-type mice, whereas no
Fgf15 mRNA was detected in Fgf15-KO mice (Figure 2A).
Notably, FGF15 protein increased from 0.8 ng/ml in plasma
from vehicle-treated mice to 6.3 ng/ml in plasma from
GW4064-treated mice (Figure 2B). As expected, FGF15 was
not detected in plasma from either vehicle or GW4064-treated
Fgf15-KO mice (Figure 2B). The GW4064-induced increases in
ileal Fgf15 expression and plasma FGF15 protein levels were
coincident with an FGF15-dependent decrease in hepatic
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Figure 3. Coordinate Diurnal Regulation of FGF15 and CYP7A1
(A) Ileal Fgf15 mRNA levels at the indicated times.
(B) Plasma FGF15 protein levels at the indicated times.
(C) Hepatic Cyp7a1 mRNA levels at the indicated times.
Ad libitum-fed C57BL/6 mice (n = 5/group, 7–9 weeks old) were acclimated for
1 week, and tissues were harvested every 3 hr at indicated time points. Lights
were turned on at 0700 and off at 1900. Data are shown as the mean ± SEM.
*p < 0.05, ***p < 0.001 compared to the lowest measured value.expression of Cyp7a1 (Figure 2C). Fgf15 mRNA was not de-
tected in liver under any of these conditions (data not shown).
As expected, GW4064 administration increased expression of
the FXR target genes Shp and Insig2 in liver of wild-type mice
(Figure S2). Interestingly, these genes were not induced by
GW4064 treatment of Fgf15-KO mice, suggesting that FGF15
contributes to the induction of at least some FXR target genes
in liver. Indeed, FGF19 treatment increases SHP expression in
rat hepatocytes (Bhatnagar et al., 2009). However, Shp overex-
pression is not sufficient to efficiently repress Cyp7a1 in mice
(Kir et al., 2012), indicating that FGF15/19 must regulate addi-
tional pathways required for the repression of bile acid synthesis.
To determinewhether FGF15 activates its receptor complex at
its circulating concentrations, we performed dose response
analysis using rat H4IIE hepatoma cells, which express both
FGFR4 and b-Klotho, and monitored ERK2 phosphorylation,
which is a well-established marker of FGFR4/b-Klotho activation
(Kurosu et al., 2007; Wu et al., 2007). Partially purified recombi-
nant FGF15 increased ERK2 phosphorylation with an EC50 ofC1 ng/ml (Figure 2D). Thus, FGF15 activates its receptor
complex at concentrations consistent with those detected in
plasma.
To determine the diurnal variation in FGF15 levels, ad libitum-
fed C57BL/6 male mice were analyzed every 3 hr over a 24 hr
period. Serum FGF15 protein levels mirrored the expected
diurnal expression of ileal Fgf15 mRNA, which peaked at
1300 hr and was lowest at 1600–1900 hr (Figures 3A and 3B).
As predicted, the diurnal regulation of FGF15 was reciprocal to
the level of hepatic Cyp7a1 expression (Figure 3C). Taken
together, these data validate the SISCAPA-SRM assay, demon-
strate unequivocally that FGF15 circulates in the blood at phys-
iologically relevant concentrations, and show that FGF15 mRNA
and protein levels correlate with decreased bile acid synthesis.
FGF15 Acts Directly on the Liver to Suppress Bile Acid
Synthesis
To test whether circulating FGF15 acts directly on the liver, we
crossed mice with a floxed allele of the b-Klotho gene (Klbfl/fl)
with albumin-Cre mice to generate Klbtm1(alb) mice in which Klb
expression was selectively eliminated in liver, but not other tis-
sues, including brown and white adipose tissue depots (Fig-
ure 4A). Groups of control Klbfl/fl and Klbtm1(alb) mice were then
administered either vehicle or FGF15. There were several impor-
tant differences between Klbfl/fl and Klbtm1(alb) mice. First, basal
Cyp7a1 expression was increased 4-fold in liver of Klbtm1(alb)
mice (Figure 4B), and there was a corresponding increase in
bile acid pool size (Figure 4C). There was also a trend toward
increased Cyp8b1 expression in the Klbtm1(alb) mice (Figure 4B),
which likely accounts at least in part for the increased fraction of
cholic acid in the bile acid pool. Second, the increase in hepatic
Cyp7a1 expression in Klbtm1(alb) mice occurred despite marked
increases in Fgf15 mRNA levels in ileum (Figure 4D) and circu-
lating FGF15 levels (Figure 4E). Third, whereas administration
of exogenous FGF15 reduced Cyp7a1 mRNA levels in control
Klbfl/fl mice, it had no effect in Klbtm1(alb)mice (Figure 4B). Finally,
Klbtm1(alb) mice had reduced hepatic glycogen concentrations
(Figure 4F), consistent with the established role of FGF15 in stim-
ulating glycogen synthesis in liver (Kir et al., 2011). Together,
these data demonstrate that FGF15 acts as a hormone on liver
to suppress bile acid synthesis and to stimulate glycogen syn-
thesis and that these effects require hepatocyte-specific expres-
sion of b-Klotho.
In summary, using SISCAPA-SRM, we demonstrate unequiv-
ocally that FGF15 acts as an FXR-regulated hormone to modu-
late bile acid synthesis and glycogen storage in liver. This study
highlights the sensitivity and utility of the SISCAPA-SRM
approach, which is likely to be broadly applicable for measuring
other low-abundance proteins. Overall, therewas a strong corre-
lation between FGF15 mRNA levels in ileum and plasma FGF15
concentrations. The circadian pattern of regulation of FGF15
observed in mouse was commensurate with that observed for
FGF19 in humans (Lunda˚sen et al., 2006). Moreover, the concen-
tration of FGF15 measured in plasma is consistent with that
required to activate its receptor. Finally, the striking induction
of FGF15 mRNA and circulating protein concentrations in the
Klbtm1(alb) mice demonstrates that this enterohepatic hormonal
signaling pathway is essential for normal feedback regulation
of bile acid homeostasis.ell Metabolism 21, 898–904, June 2, 2015 ª2015 Elsevier Inc. 901
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Figure 4. Hepatic Expression of b-Klotho Is
Required for Normal Bile Acid and Carbohy-
drate Metabolism
(A) Klb gene expression in tissues from ad libitum-
fed WT (open bars) and Klbtm1(alb) (filled bars) mice
(n.d., not detected).
(B) HepaticCyp7a1 andCyp8b1mRNA levels in ad
libitum-fed WT and Klbtm1(alb) mice treated with
vehicle (open bars) or 1 mg/kg FGF15 (filled bars).
Mice were injected with FGF15 when the lights
were turned on and were killed 6 hr later.
(C) Bile acid pool size in WT and Klbtm1(alb) mice as
in (B) (***p < 0.001 comparing total pool sizes).
(D) Fgf15mRNA levels in ileum from same mice as
in (B).
(E) Plasma FGF15 levels in same mice as in (B).
(F) Hepatic glycogen levels in same mice as in (B).
Data are shown as the mean ± SEM; n = 4–6.
*p < 0.05, **p < 0.01, ***p < 0.001.EXPERIMENTAL PROCEDURES
FGF15 Peptide Synthesis and Antisera
Peptide synthesis and rabbit antisera generation against FGF15 (GenBank:
AAO13811.1) fragments FGF15-52 (LQYLYSAGPYVSNCFLR), FGF15-176
(SFFETGDQLR), and FGF15-188 (MFSLPLESDSMDPFR) were performed by
Bethyl Laboratories. The peptides were conjugated to KLH, and Complete
Freund’s Adjuvant was used to elicit an immune response. Antibodies against
the synthetic peptide antigens were purified by peptide affinity chromatog-
raphy by Bethyl Laboratories and evaluated by measurement of binding activ-
ity to the serially diluted peptide plated onto an ELISA plate. Peptides were
serially diluted with 100 mM Na2CO3 (pH 9.6) and applied in a 100 ml volume
to 96-well Nunc high-binding plates (Thermo Fisher Scientific) at 4C for
12 hr. Total amounts of peptides applied to the plates ranged from
0.001 nmol to 1000 nmol/well (Figure S1). After washing 3 times in PBS con-
taining 0.1% Tween 20 (PBS-T), plates were blocked with PBS-T containing
1% BSA (300 ml/well) at room temperature for 3 hr. Antibodies (1 mg/ml)
against the corresponding peptides were diluted 1:1,500, 1:15,000, and
1:150,000 with PBS-T containing 1% BSA, added to plates (100 ml/well),
and incubated overnight at 4C. Plates were washed 3 times with PBS-T,
and 100 ml of anti-rabbit IgG conjugated with horseradish peroxidase902 Cell Metabolism 21, 898–904, June 2, 2015 ª2015 Elsevier Inc.(1:1,000 dilution, Millipore) was added to the wells
for 2 hr at room temperature. Plates were washed 5
times with PBS-T, and 50 ml/well of 3,30,5,50-tetra-
methylbenzidine solution (Thermo) was added
followed by 0.18 M H2SO4 (50 ml/well). Antibody
binding to peptides was quantified by measuring
absorbance at optical density 450 (OD450). Stable
heavy-isotope-labeled peptides were synthesized
by 21st Century Biochemicals with purities of
>85% as determined by HPLC. All peptides were
synthesized with a C-terminal [13C6,
15N4] arginine,
and all cysteines were carbamidomethylated.
These peptides were used without further
purification.
Immunopurification of FGF15 Peptides
30 ml of mouse systemic plasma were mixed with
the same volume of 100 mM Tris (pH 8.0) and
60 ml of trifluoroethanol and mixed vigorously for
30 s. Following the addition of Tris (2-carboxyethyl)
phosphine HCl (5 mM final concentration) and
reduction of the samples at room temperature for
30 min with gentle agitation, iodoacetamide
(2.5 mM final concentration) was added, and thesamples were alkylated at room temperature for 30 min in the dark. Trypsin
digestion was performed by adding 1.08 ml of 100 mM Tris-HCl (pH 8.0) and
40 ml of a 1 mg/ml trypsin solution (proteomics-grade trypsin, Sigma) and incu-
bating the samples at 37C overnight. The digestion was completed by adding
the same amount of the trypsin solution and incubating the samples for 4 hr at
37C, and the reaction was terminated by addition of 13 ml each of formic acid
(50%) and 10% trifluoroacetic acid (TFA). Complete digestionwas confirmed
by SDS-PAGE/silver stain analysis. 20 fmol of stable isotope-labeled peptide
were added prior to purification, for subsequent quantification and to account
for variation in sample recovery. The trypsin-digested peptides were eluted
from an Oasis HLB plate with 80% acetonitrile containing 0.1% TFA, and the
solvent was evaporated in a SpeedVac concentrator. The samples were solu-
bilized in 50 ml PBS containing 0.04% RapiGest and sonicated.
For antibody immobilization reactions, 15 ml of FGF15 peptide fragment anti-
serum were mixed with 10 ml of protein G agarose beads (50% slurry; Santa
Cruz) and 25 ml of PBS and incubated for 45 min at room temperature with
gentle shaking. The antibody-protein G beads were washed twice with
0.2 M triethanolamine/PBS (pH 8.5) and conjugated with 25 mM dimethyl
pimelimidate (DMP) at room temperature for 30 min with gentle shaking. The
excess DMP was quenched by washing the conjugated beads twice with
0.2M ethanolamine/PBS (pH 8.0) for 5 min. The conjugated beads were rinsed
three times with PBS containing 0.04% RapiGest, and 50 ml of antibody
beads (20% slurry) were mixed with the sample reconstituted as described
above and incubated at 4C with gentle shaking overnight. The beads were
rinsed twice with PBS containing 0.04% RapiGest, three times with PBS,
and once with 0.13 PBS. The peptides were eluted from the beads with
30 ml of 5% acetic acid. After 5 min, the samples were centrifuged, and
the supernatant containing the enriched peptides was dried in a SpeedVac
concentrator and reconstituted in 100 ml of 0.5% TFA. This sample was incu-
bated at 37C with shaking for 45 min and then centrifuged at 13,000 rpm
for 10 min to remove insoluble materials. The supernatant was cleaned by
solid phase extraction on a Waters Oasis HLB plate, eluted with 40%
ACN, 0.1% TFA, and dried in a SpeedVac concentrator. The sample was re-
constituted in 6 ml of 98% water, 2% acetonitrile, 0.1% TFA for mass spec-
trometry analysis.
MS Analysis
The FGF15 enriched samples were analyzed using a Q Exactive mass spec-
trometer (Thermo Scientific) coupled to an Ultimate 3000 RSLCnano HPLC
system (Dionex). Peptides were loaded onto a 75 mm (inner diameter) 3
50 cm column packed in-house with a reverse-phase material ReproSil-Pur
C18-AQ, 1.9 mm resin (Dr. Maisch GmbH, Ammerbuch-Entringen, Germany).
Peptides were eluted with a gradient comprised of 1%–41% B in 40 min and
41%–80% B in 10 min, where mobile phase A was 0.1% formic acid in water
and mobile phase B was 0.1% formic acid in acetonitrile. The column temper-
ature was maintained at 60C using a butterfly heater (Phoenix S&T). The
shotgun analysis was performed using a data-dependent top 20 method,
with the full MS scans acquired at 70 K resolution (at m/z 200) and MS/MS
scans acquired at 17.5 K resolution (at m/z 200). The under-fill ratio was set
at 0.3%, with a 3 m/z isolation window and fixed first mass of m/z 100 for
theMS/MS acquisitions. Charge exclusion was applied to exclude unassigned
and charge +1 species, and dynamic exclusion was usedwith a duration of 7 s.
The data were then searched using CPFP version 2.0.3. (Trudgian andMirzaei,
2012; Trudgian et al., 2010)
SRM
The top seven transitions for each heavy-labeled peptide were determined by
monitoring peak areas for all singly charged b and y ions below m/z = 1,250
and for all doubly and triply charged peptide ions below m/z = 1,000, for a
1 ml injection of 50 fmol of a mix of each of the three heavy-labeled peptide
standards. These data were analyzed using Skyline v1.4 (http://skyline.
maccosslab.org) (MacLean et al., 2010), and collision energies and decluster-
ing potentials were generated by the software without additional user optimi-
zation. Lists of the transitions, retention times, declustering potentials, and
collision energies used are given in Table S2. Transitions that had interference
from impurities or noise peaks were not included when performing peptide
quantifications.
Spiked plasma samples were separated on a Dionex Acclaim PepMap100
reverse-phase C18 column (75 mm 3 15 cm) using an Ultimate 3000
RSLCnano HPLC system. The HPLCwas controlled using Chromeleon Xpress
(version 6.8 SR10) and Dionex ChromatographyMS Link v. 2.12. Separation of
peptides was carried out at 200 nl/min using a gradient from 0%–25% B for
45 min, 25%–35% B for 10 min, and 35%–80% B for 5 min, where mobile
phase A was 0.1% formic acid in water and mobile phase B was 0.1% formic
acid in acetonitrile. Mass spectrometric analysis was performed on an AB
Sciex 6500 QTRAP mass spectrometer in positive-ion low-mass mode, using
a NanoSpray III source with a New Objective precut 360 m PicoTip emitter
(FS360-20-10-N20-10.5CT). The source settings were as follows: curtain
gas = 35, ion spray voltage = 2,550, ion source gas 1 = 6. Analyst Software
v.1.6 was used to run the mass spectrometer. SRM data were analyzed using
Multiquant v.2.1 (AB Sciex).
To determine the LOD of FGF15 by SRM alone (without antibody enrich-
ment), we prepared a sample containing 100 mg of mouse plasma digest
spiked with 100 fmol of heavy-labeled FGF15-176. Mouse plasma digest
was used to account for the matrix effect on the LOD for FGF15 measured
by SRM. We injected 2 mg of spiked plasma digest onto the column, and
based on the signal we extrapolated the LOD (S/N = 3) for FGF15 to be
75 amol, which translates to 42.3 ng/ml in plasma, assuming that FGF15
was completely digested and the measurements were within the linear dy-Cnamic range of the instrument. The LOD for SISCAPA is determined by
many factors, including the LOD of the SRM method, the anti-peptide anti-
body affinity for the targeted peptide, the concentration of FGF15 in the
sample, and the sample size. We were able to routinely detect and quantify
FGF15 by SISCAPA using 30 ml of mouse plasma, with an LOD of 0.1 ng/ml
(S/N = 3), which is over 400 times less than the LOD for SRM analysis
alone.
Mouse Experiments
All experiments were approved by the Institutional Animal Care and Research
Advisory Committee of the University of Texas Southwestern Medical Center.
Littermate male mice on a C57BL/6 backgroundmaintained on a 12 hr light cy-
cle (lights on at ZT0700) were used for all experiments. Fgf15-KO mice were
generated previously (Wright et al., 2004) and maintained in our facility. The
Klb gene was deleted from hepatocytes by crossing Klbfl/fl mice (Ding et al.,
2012) with albumin-Cre mice (The Jackson Laboratory). Liver-specific disrup-
tion of Klb was confirmed by real-time PCR. For FXR agonist studies, WT or
Fgf15-KO mice were fasted 5 hr before oral gavage with vehicle or GW4064
(100 mg/ml in 1% methylcellulose and 0.1% Tween 80). For recombinant
FGF15 studies, 1 mg/kg of FGF15 was intraperitoneally injected into ad libi-
tum-fed WT or Klbtm1(alb) mice in a volume of 1 ml/100 g body weight saline
(see below for preparation and quantification of purified protein). 5 hr later
the mice were sacrificed by carbon dioxide inhalation, and tissues were har-
vested. Plasma was harvested from the left cardiac ventricle using an insulin
syringe with a 29G needle (BD). The blood was transferred to an EDTA tube
(Sarstedt) and centrifuged at 1,000 3 g for 5 min. The plasma was transferred
to a 1.5 ml microfuge tube (Eppendorf) and immediately frozen in liquid nitro-
gen. Tissues were directly harvested into Trizol reagent, disrupted, and frozen
in liquid nitrogen.
Bile Acid Measurement
Bile acid pool size was measured as described previously (Schmidt et al.,
2010). Briefly, liver, gallbladder, intestines, and attached mesentery were
collected and bile acids extracted by homogenization and boiling. Individual
bile acid compositions were determined by MS equipped with high-perfor-
mance liquid chromatography using the following bile salts as standards:
tauro-b-muricholate, tauroursodeoxycholate, taurohyodeoxycholate, tauro-
cholate (TCA), glycocholate, taurochenodeoxycholate, taurodeoxycholate,
glycochenodeoxycholate, glycodeoxycholate, and taurolithocholate. Tauro-
b-muricholate was purchased from Steraloids. All the other bile acids were
purchased from Sigma.
Liver Glycogen Content
Hepatic glycogen concentrations were measured as described (Kir et al.,
2011).
Recombinant FGF15
Full-length mouse FGF15 cDNA harboring 6 histidine residues at the C termi-
nus (6x His-tagged) was subcloned into the pLVX-IRES-ZsGreen lentiviral vec-
tor (pLVX-FGF15). The lentiviral particles were generated by transfecting
pLVX-FGF15 together with D8.9 and VSVG plasmids into Lenti-X 293T cells
(Clontech). Lenti-X 293T cells were infected with the virus, and 6x His-tagged
FGF15 protein was purified using Ni-NTA resin (QIAGEN). To accurately deter-
mine the concentration of FGF15 in this partially purified preparation, the re-
combinant protein was quantified by SISCAPA.
Hepatoma Cell Line Experiments
H4IIE cells (ATCC) were maintained in Eagle’s minimal essential medium
(EMEM) supplemented with 10% heat-inactivated FBS. Cells were seeded
onto 24-well plates and maintained until they reached >70% confluence, at
which point the culture medium was replaced with DMEM containing 20 mM
HEPES (pH 7.3), and the cells were cultured overnight. 2 hr prior to FGF15
treatment, the medium was replaced with fresh DMEM containing 20 mM
HEPES (pH 7.3). Cells were treated with FGF15 for 10 min, the medium was
removed, and 13 SDS-PAGE sample buffer containing 2% 2-mercaptoetha-
nol was added. Total ERK2 and phosphorylated ERK2 in the cell suspension
were quantified by western blot analysis using antibodies purchased from
Cell Signaling.ell Metabolism 21, 898–904, June 2, 2015 ª2015 Elsevier Inc. 903
qRT-PCR
Liver and ileum RNAs were extracted using Trizol (Invitrogen) according to
manufacturer’s protocol. Adipose tissue RNA was purified using RNeasy lipid
tissue RNA purification kit. Purified RNA was treated with DNase and reverse
transcribed with Multiscribe (Invitrogen) in the presence of random hexamer.
The following primers were used for qPCR of individual mouse gene expres-
sion. Cyp7a1: 50-agcaactaaacaacctgccagtacta-30, 50-gtccggatattcaaggatg
ca-30; Cyp8b1: 50-gccttcaagtatgatcggttcct-30, 50-gatcttcttgcccgacttgtaga-30;
Fgf15: 50-acgggctgattcgctactc-30, 50-tgtagcctaaacagtccatttcct-30; Klb: 50-gat
gaagaatttcctaaaccaggtt-30, 50-aaccaaacacgcggatttc-30. RelativemRNA levels
were calculated using the comparative Ct method normalized to U36b4.
Statistical Analysis
Statistical analyses were performed by 2-way ANOVAwith post hoc correction
(GraphPad Prism) unless indicated otherwise. Data are presented as the
mean ± SEM; p < 0.05 was considered significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
two figures, and two tables and can be found with this article online at
http://dx.doi.org/10.1016/j.cmet.2015.05.004.
AUTHOR CONTRIBUTIONS
T.K. conducted and analyzed all experiments involving mice, cell lines, and
preparation of samples for SISCAPA-SRM. D.E. initiated the project and de-
signed, conducted, and analyzed experiments to develop FGF15 peptides
and antisera and mouse experiments. X.D. generated Klbtm1(alb) mice. A.L.
conducted and analyzed all MS experiments. V.S. performed the measure-
ment and analysis of bile acids. H.M., S.A.K., and D.J.M. designed and super-
vised the project and wrote the paper.
ACKNOWLEDGMENTS
We thank Yuan Zhang and Heather Lawrence for technical assistance. This
work was supported by NIH grant R01DK067158 (S.A.K. and D.J.M.), the Rob-
ert A.Welch Foundation (grant I-1558 to S.A.K. and grant I-1275 to D.J.M.), the
Cancer Prevention and Research Institute of Texas (grants R1121 and
RP120613 to H.M.), a Swiss National Foundation Early Postdoc Mobility
Fellowship (D.E.), and the Howard Hughes Medical Institute (D.J.M.). X.D. is
an employee and stockholder of NGM Biopharmaceuticals.
Received: January 9, 2015
Revised: March 18, 2015
Accepted: April 24, 2015
Published: June 2, 2015
REFERENCES
Anderson, N.L., Anderson, N.G., Haines, L.R., Hardie, D.B., Olafson, R.W., and
Pearson, T.W. (2004). Mass spectrometric quantitation of peptides and pro-
teins using Stable Isotope Standards and Capture by Anti-Peptide
Antibodies (SISCAPA). J. Proteome Res. 3, 235–244.
Angelin, B., Larsson, T.E., and Rudling, M. (2012). Circulating fibroblast growth
factors as metabolic regulators—a critical appraisal. Cell Metab. 16, 693–705.
Beenken, A., andMohammadi, M. (2009). The FGF family: biology, pathophys-
iology and therapy. Nat. Rev. Drug Discov. 8, 235–253.
Bhatnagar, S., Damron, H.A., and Hillgartner, F.B. (2009). Fibroblast growth
factor-19, a novel factor that inhibits hepatic fatty acid synthesis. J. Biol.
Chem. 284, 10023–10033.
de Aguiar Vallim, T.Q., Tarling, E.J., and Edwards, P.A. (2013). Pleiotropic roles
of bile acids in metabolism. Cell Metab. 17, 657–669.
Ding, X., Boney-Montoya, J., Owen, B.M., Bookout, A.L., Coate, K.C.,
Mangelsdorf, D.J., and Kliewer, S.A. (2012). bKlotho is required for fibroblast
growth factor 21 effects on growth and metabolism. Cell Metab. 16, 387–393.904 Cell Metabolism 21, 898–904, June 2, 2015 ª2015 Elsevier Inc.Goodwin, B., Jones, S.A., Price, R.R., Watson, M.A., McKee, D.D., Moore,
L.B., Galardi, C., Wilson, J.G., Lewis, M.C., Roth, M.E., et al. (2000). A regula-
tory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile
acid biosynthesis. Mol. Cell 6, 517–526.
Hortin, G.L., and Sviridov, D. (2010). The dynamic range problem in the anal-
ysis of the plasma proteome. J. Proteomics 73, 629–636.
Inagaki, T., Choi, M., Moschetta, A., Peng, L., Cummins, C.L., McDonald, J.G.,
Luo, G., Jones, S.A., Goodwin, B., Richardson, J.A., et al. (2005). Fibroblast
growth factor 15 functions as an enterohepatic signal to regulate bile acid ho-
meostasis. Cell Metab. 2, 217–225.
Katoh,M., andKatoh,M. (2003). EvolutionaryconservationofCCND1-ORAOV1-
FGF19-FGF4 locus from zebrafish to human. Int. J. Mol. Med. 12, 45–50.
Kir, S., Beddow, S.A., Samuel, V.T., Miller, P., Previs, S.F., Suino-Powell, K.,
Xu, H.E., Shulman, G.I., Kliewer, S.A., and Mangelsdorf, D.J. (2011). FGF19
as a postprandial, insulin-independent activator of hepatic protein and
glycogen synthesis. Science 331, 1621–1624.
Kir, S., Zhang, Y., Gerard, R.D., Kliewer, S.A., and Mangelsdorf, D.J. (2012).
Nuclear receptors HNF4a and LRH-1 cooperate in regulating Cyp7a1 in vivo.
J. Biol. Chem. 287, 41334–41341.
Kurosu, H., Choi, M., Ogawa, Y., Dickson, A.S., Goetz, R., Eliseenkova, A.V.,
Mohammadi, M., Rosenblatt, K.P., Kliewer, S.A., and Kuro-o, M. (2007).
Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) re-
ceptor isoforms determines metabolic activity of FGF19 and FGF21. J. Biol.
Chem. 282, 26687–26695.
Lunda˚sen, T., Ga¨lman, C., Angelin, B., and Rudling, M. (2006). Circulating in-
testinal fibroblast growth factor 19 has a pronounced diurnal variation and
modulates hepatic bile acid synthesis in man. J. Intern. Med. 260, 530–536.
MacLean, B., Tomazela, D.M., Shulman, N., Chambers, M., Finney, G.L.,
Frewen, B., Kern, R., Tabb, D.L., Liebler, D.C., and MacCoss, M.J. (2010).
Skyline: an open source document editor for creating and analyzing targeted
proteomics experiments. Bioinformatics 26, 966–968.
Mirzaei, H., Knijnenburg, T.A., Kim, B., Robinson, M., Picotti, P., Carter, G.W.,
Li, S., Dilworth, D.J., Eng, J.K., Aitchison, J.D., et al. (2013). Systematic mea-
surement of transcription factor-DNA interactions by targetedmass spectrom-
etry identifies candidate gene regulatory proteins. Proc. Natl. Acad. Sci. USA
110, 3645–3650.
Picotti, P., Cle´ment-Ziza, M., Lam, H., Campbell, D.S., Schmidt, A., Deutsch,
E.W., Ro¨st, H., Sun, Z., Rinner, O., Reiter, L., et al. (2013). A complete mass-
spectrometric map of the yeast proteome applied to quantitative trait analysis.
Nature 494, 266–270.
Potthoff,M.J., Kliewer, S.A., andMangelsdorf, D.J. (2012). Endocrine fibroblast
growth factors 15/19 and 21: from feast to famine. Genes Dev. 26, 312–324.
Schmidt, D.R., Holmstrom, S.R., Fon Tacer, K., Bookout, A.L., Kliewer, S.A.,
and Mangelsdorf, D.J. (2010). Regulation of bile acid synthesis by fat-soluble
vitamins A and D. J. Biol. Chem. 285, 14486–14494.
Trudgian, D.C., and Mirzaei, H. (2012). Cloud CPFP: a shotgun proteomics
data analysis pipeline using cloud and high performance computing.
J. Proteome Res. 11, 6282–6290.
Trudgian, D.C., Thomas, B., McGowan, S.J., Kessler, B.M., Salek, M., and
Acuto, O. (2010). CPFP: a central proteomics facilities pipeline.
Bioinformatics 26, 1131–1132.
Walters, J.R., Tasleem, A.M., Omer, O.S., Brydon, W.G., Dew, T., and le Roux,
C.W. (2009). A new mechanism for bile acid diarrhea: defective feedback inhi-
bition of bile acid biosynthesis. Clin. Gastroenterol. Hepatol. 7, 1189–1194.
Wright, T.J., Ladher, R., McWhirter, J., Murre, C., Schoenwolf, G.C., and
Mansour, S.L. (2004). Mouse FGF15 is the ortholog of human and chick
FGF19, but is not uniquely required for otic induction. Dev. Biol. 269, 264–275.
Wu, X., Ge,H., Gupte, J.,Weiszmann, J., Shimamoto,G., Stevens, J., Hawkins,
N., Lemon, B., Shen, W., Xu, J., et al. (2007). Co-receptor requirements for
fibroblast growth factor-19 signaling. J. Biol. Chem. 282, 29069–29072.
Yu, C., Wang, F., Kan, M., Jin, C., Jones, R.B., Weinstein, M., Deng, C.X., and
McKeehan, W.L. (2000). Elevated cholesterol metabolism and bile acid syn-
thesis in mice lacking membrane tyrosine kinase receptor FGFR4. J. Biol.
Chem. 275, 15482–15489.
